Innate Begin Period Cash Flow vs End Period Cash Flow Analysis

IPHA Stock

USD 1.54 0.04 2.67%

Innate Pharma financial indicator trend analysis is infinitely more than just investigating Innate Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Innate Pharma is a good investment. Please check the relationship between Innate Pharma Begin Period Cash Flow and its End Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

Begin Period Cash Flow vs End Period Cash Flow

Begin Period Cash Flow vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Innate Pharma Begin Period Cash Flow account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Innate Pharma's Begin Period Cash Flow and End Period Cash Flow is 0.72. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Innate Pharma, assuming nothing else is changed. The correlation between historical values of Innate Pharma's Begin Period Cash Flow and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Innate Pharma are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Innate Pharma's Begin Period Cash Flow and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

End Period Cash Flow

Most indicators from Innate Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.The current year's Selling General Administrative is expected to grow to about 14.6 M, whereas Discontinued Operations is forecasted to decline to (123.8 K).

	2021	2022	2023	2024 (projected)
Interest Income	6.3M	4.8M	3.2M	4.6M
Reconciled Depreciation	4.6M	45.4M	5.1M	4.8M

Interest Income Reconciled Depreciation

Innate Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Net Receivables
Total Assets		0.14	0.79	0.9	0.87	0.77	0.81	-0.85	-0.33	0.77	0.92	0.88	0.41	0.89	0.63	0.62	0.4	0.72	0.05	0.69	0.95	0.75	0.95	0.02	0.67	0.55
Short Long Term Debt Total	0.14		-0.05	0.02	0.09	0.28	-0.35	0.26	-0.89	-0.13	0.04	0.27	0.54	0.03	0.64	0.7	-0.05	0.24	0.87	0.65	0.15	0.4	0.04	0.64	0.66	-0.21
Other Current Liab	0.79	-0.05		0.81	0.64	0.35	0.75	-0.65	-0.1	0.88	0.66	0.55	0.36	0.71	0.34	0.29	0.54	0.52	-0.03	0.39	0.78	0.34	0.84	-0.11	0.36	0.69
Total Current Liabilities	0.9	0.02	0.81		0.79	0.65	0.86	-0.72	-0.16	0.66	0.76	0.78	0.09	0.69	0.44	0.4	0.18	0.46	-0.06	0.51	0.85	0.62	0.87	0.04	0.47	0.79
Total Stockholder Equity	0.87	0.09	0.64	0.79		0.78	0.59	-0.78	-0.22	0.53	0.83	0.9	0.31	0.73	0.58	0.53	0.08	0.35	-0.11	0.65	0.67	0.73	0.75	0.0	0.62	0.43
Property Plant And Equipment Net	0.77	0.28	0.35	0.65	0.78		0.49	-0.64	-0.4	0.38	0.74	0.85	0.26	0.62	0.7	0.71	-0.04	0.47	0.04	0.7	0.66	0.95	0.62	0.17	0.76	0.25
Current Deferred Revenue	0.81	-0.35	0.75	0.86	0.59	0.49		-0.85	0.15	0.78	0.78	0.57	-0.01	0.78	0.18	0.14	0.44	0.58	-0.32	0.21	0.84	0.43	0.86	-0.24	0.2	0.67
Net Debt	-0.85	0.26	-0.65	-0.72	-0.78	-0.64	-0.85		-0.08	-0.73	-0.95	-0.66	-0.21	-0.92	-0.37	-0.33	-0.43	-0.61	0.32	-0.37	-0.78	-0.57	-0.87	0.24	-0.4	-0.39
Retained Earnings	-0.33	-0.89	-0.1	-0.16	-0.22	-0.4	0.15	-0.08		-0.07	-0.2	-0.38	-0.56	-0.2	-0.77	-0.81	-0.09	-0.44	-0.86	-0.81	-0.35	-0.54	-0.25	-0.36	-0.79	0.06
Accounts Payable	0.77	-0.13	0.88	0.66	0.53	0.38	0.78	-0.73	-0.07		0.72	0.52	0.5	0.84	0.28	0.28	0.8	0.74	-0.08	0.31	0.82	0.33	0.84	-0.16	0.31	0.45
Cash	0.92	0.04	0.66	0.76	0.83	0.74	0.78	-0.95	-0.2	0.72		0.76	0.38	0.97	0.56	0.54	0.43	0.7	-0.06	0.57	0.85	0.7	0.91	-0.06	0.6	0.34
Non Current Assets Total	0.88	0.27	0.55	0.78	0.9	0.85	0.57	-0.66	-0.38	0.52	0.76		0.41	0.68	0.66	0.65	0.13	0.51	0.01	0.75	0.75	0.81	0.7	0.19	0.71	0.34
Non Currrent Assets Other	0.41	0.54	0.36	0.09	0.31	0.26	-0.01	-0.21	-0.56	0.5	0.38	0.41		0.51	0.53	0.59	0.64	0.62	0.45	0.55	0.42	0.31	0.36	0.38	0.55	-0.25
Cash And Short Term Investments	0.89	0.03	0.71	0.69	0.73	0.62	0.78	-0.92	-0.2	0.84	0.97	0.68	0.51		0.51	0.5	0.65	0.81	-0.01	0.52	0.88	0.59	0.92	-0.08	0.54	0.28
Common Stock Total Equity	0.63	0.64	0.34	0.44	0.58	0.7	0.18	-0.37	-0.77	0.28	0.56	0.66	0.53	0.51		0.98	0.12	0.56	0.47	0.96	0.59	0.84	0.54	0.28	0.99	0.08
Common Stock Shares Outstanding	0.62	0.7	0.29	0.4	0.53	0.71	0.14	-0.33	-0.81	0.28	0.54	0.65	0.59	0.5	0.98		0.15	0.62	0.53	0.95	0.6	0.82	0.52	0.35	0.98	0.04
Short Term Investments	0.4	-0.05	0.54	0.18	0.08	-0.04	0.44	-0.43	-0.09	0.8	0.43	0.13	0.64	0.65	0.12	0.15		0.76	0.08	0.12	0.55	-0.02	0.52	-0.11	0.12	-0.01
Non Current Liabilities Total	0.72	0.24	0.52	0.46	0.35	0.47	0.58	-0.61	-0.44	0.74	0.7	0.51	0.62	0.81	0.56	0.62	0.76		0.3	0.56	0.86	0.51	0.76	0.0	0.57	0.15
Other Current Assets	0.05	0.87	-0.03	-0.06	-0.11	0.04	-0.32	0.32	-0.86	-0.08	-0.06	0.01	0.45	-0.01	0.47	0.53	0.08	0.3		0.48	0.14	0.21	0.06	0.36	0.47	-0.08
Other Stockholder Equity	0.69	0.65	0.39	0.51	0.65	0.7	0.21	-0.37	-0.81	0.31	0.57	0.75	0.55	0.52	0.96	0.95	0.12	0.56	0.48		0.63	0.8	0.57	0.25	0.97	0.15
Total Liab	0.95	0.15	0.78	0.85	0.67	0.66	0.84	-0.78	-0.35	0.82	0.85	0.75	0.42	0.88	0.59	0.6	0.55	0.86	0.14	0.63		0.66	0.96	0.02	0.61	0.55
Property Plant And Equipment Gross	0.75	0.4	0.34	0.62	0.73	0.95	0.43	-0.57	-0.54	0.33	0.7	0.81	0.31	0.59	0.84	0.82	-0.02	0.51	0.21	0.8	0.66		0.62	0.21	0.86	0.24
Total Current Assets	0.95	0.04	0.84	0.87	0.75	0.62	0.86	-0.87	-0.25	0.84	0.91	0.7	0.36	0.92	0.54	0.52	0.52	0.76	0.06	0.57	0.96	0.62		-0.1	0.56	0.62
Short Term Debt	0.02	0.64	-0.11	0.04	0.0	0.17	-0.24	0.24	-0.36	-0.16	-0.06	0.19	0.38	-0.08	0.28	0.35	-0.11	0.0	0.36	0.25	0.02	0.21	-0.1		0.3	-0.18
Common Stock	0.67	0.66	0.36	0.47	0.62	0.76	0.2	-0.4	-0.79	0.31	0.6	0.71	0.55	0.54	0.99	0.98	0.12	0.57	0.47	0.97	0.61	0.86	0.56	0.3		0.08
Net Receivables	0.55	-0.21	0.69	0.79	0.43	0.25	0.67	-0.39	0.06	0.45	0.34	0.34	-0.25	0.28	0.08	0.04	-0.01	0.15	-0.08	0.15	0.55	0.24	0.62	-0.18	0.08

Click cells to compare fundamentals

Innate Pharma Account Relationship Matchups

Innate Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	401.4M	307.4M	267.5M	207.9M	184.2M	188.0M
Short Long Term Debt Total	18.7M	19.1M	44.3M	42.3M	39.9M	41.9M
Other Current Liab	43.0M	14.3M	14.4M	13.0M	15.1M	14.8M
Total Current Liabilities	121.8M	46.7M	79.9M	41.3M	39.6M	48.6M
Total Stockholder Equity	217.4M	156.0M	107.4M	54.2M	51.9M	81.7M
Property Plant And Equipment Net	11.7M	11.7M	10.2M	8.5M	6.3M	7.9M
Current Deferred Revenue	48.8M	12.5M	12.5M	6.6M	5.9M	5.6M
Net Debt	(184.2M)	(117.7M)	(59.5M)	(42.0M)	(30.7M)	(32.2M)
Retained Earnings	(155.7M)	(220.5M)	(272.2M)	(330.3M)	(336.9M)	(320.0M)
Accounts Payable	27.9M	20.7M	14.7M	13.7M	8.6M	17.0M
Cash	202.9M	136.8M	103.8M	84.2M	70.6M	84.5M
Non Current Assets Total	163.8M	134.1M	129.2M	68.0M	36.2M	55.5M
Non Currrent Assets Other	16.8M	30.1M	30.0M	14.2M	19.6M	20.6M
Cash And Short Term Investments	218.9M	151.6M	119.8M	101.5M	92.5M	106.4M
Common Stock Total Equity	2.9M	3.2M	3.9M	4.0M	4.5M	2.5M
Common Stock Shares Outstanding	66.9M	78.9M	79.5M	79.6M	80.5M	53.1M
Short Term Investments	16.0M	14.8M	16.1M	17.3M	21.9M	16.8M
Liabilities And Stockholders Equity	401.4M	307.4M	267.5M	207.9M	184.2M	188.0M
Non Current Liabilities Total	62.1M	104.8M	80.2M	112.4M	92.7M	57.7M
Other Stockholder Equity	369.6M	372.1M	375.2M	379.6M	384.3M	216.7M
Total Liab	183.9M	151.4M	160.1M	153.7M	132.3M	106.3M
Property Plant And Equipment Gross	11.7M	11.7M	10.2M	8.5M	9.8M	8.0M
Total Current Assets	237.6M	173.3M	138.3M	139.8M	148.0M	132.5M
Short Term Debt	2.1M	2.1M	30.7M	2.1M	8.9M	9.4M
Common Stock	3.9M	4.0M	4.0M	4.0M	4.0M	2.8M
Net Receivables	13.1M	10.6M	846K	3.1M	15.2M	21.7M
Accumulated Other Comprehensive Income	(472K)	355K	456K	819K	495K	519.8K
Inventory	5.6M	1.0	(4.9M)	(2K)	(3.4M)	(3.2M)
Intangible Assets	97.0M	46.3M	44.2M	42.6M	416K	395.2K
Other Liab	45.5M	87.8M	66.7M	72.2M	65.0M	74.7M
Net Tangible Assets	120.4M	109.7M	63.2M	52.6M	60.5M	84.3M
Long Term Debt	14.1M	16.9M	13.5M	38.9M	30.6M	32.1M
Capital Lease Obligations	3.1M	3.5M	2.8M	2.1M	835K	793.3K
Long Term Investments	37.0M	38.9M	39.9M	35.1M	9.8M	9.3M
Short Long Term Debt	1.5M	2.1M	30.7M	1.3M	8.5M	5.6M
Property Plant Equipment	11.7M	11.7M	10.2M	8.5M	9.8M	10.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:

How To Invest In Innate

Details

Is Innate Stock a good investment?

Details

What is Innate Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.75)

Earnings Share

(0.44)

Revenue Per Share

0.419

Quarterly Revenue Growth

(0.69)

Return On Assets

(0.14)

The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Innate Begin Period Cash Flow vs End Period Cash Flow Analysis

Begin Period Cash Flow vs End Period Cash Flow

Begin Period Cash Flow vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

End Period Cash Flow

Innate Pharma fundamental ratios Correlations

Innate Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Innate Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 0.99	Common Stock Total Equity
Common Stock Shares Outstanding	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.97	Cash
Common Stock	+ 0.97	Other Stockholder Equity
Other Stockholder Equity	+ 0.96	Common Stock Total Equity

Cash	- 0.95	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Retained Earnings	- 0.89	Short Long Term Debt Total
Total Current Assets	- 0.87	Net Debt
Other Current Assets	- 0.86	Retained Earnings
Net Debt	- 0.85	Current Deferred Revenue